Patent strategy in pharmaceutical industry : are additional patents valuable?

Patent strategy in pharmaceutical industry are additional patents valuable?

This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product...

Descripción completa

Detalles Bibliográficos
Otros Autores: Donghi, Monica, author (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Baden-Baden, [Germany] : Nomos Verlagsgesellschaft mbH & Co. KG 2014
2014.
Edición:1. Auflage
Colección:MIPLC studies ; Volume 20.
Materias:
Patent medicines > Law and legislation > European Union countries.
Drugs > Patents > Economic aspects > European Union countries.
Patent medicines > European Union countries > Case studies.
Markenrecht
Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht
Gewerblicher Rechtsschutz
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009424525806719
Tabla de Contenidos:
  • Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry - The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices
  • f) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German
  • Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others

Ejemplares similares